Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

KRAS G12C inhibitor

DRUG CLASS:

KRAS G12C inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + adagrasib Sensitive: A1 - Approval cetuximab + adagrasib Sensitive : A1	cetuximab + adagrasib Sensitive: A1 - Approval cetuximab + adagrasib Sensitive : A1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: A1 - Approval panitumumab + sotorasib Sensitive : A1	panitumumab + sotorasib Sensitive: A1 - Approval panitumumab + sotorasib Sensitive : A1
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2